by Market Overview:
Cell therapy involves using live whole cells to treat diseases like cancer and other conditions. The cell therapy manufacturing process uses various technologies and methods at large scale to produce therapeutic cells in compliance with regulatory standards. This includes cell isolation, culture, quality checks, formulation, cryopreservation and packaging. The applications of cell therapy manufacturing include production of stem cells, T cells and NK cells for cancer immunotherapy as well as regenerative medicine for wound healing.
Market Dynamics:
The rising prevalence of chronic diseases like cancer is expected to drive the demand for cell therapy manufacturing over the forecast period. According to WHO, cancer burden is projected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. This has increased the R&D activities in cell-based immunotherapies. Additionally, advancement in cell therapy technologies such as CRISPR, cell culture media and controlled bioreactors have improved the manufacturing processes, reduced costs and increased production capacities. These factors are projected to fuel the market growth during 2023-2030 period. However, stringent regulatory processes and high costs associated with cell therapy development pose a challenge to market expansion.
Segment Analysis
The global cell therapy manufacturing market is dominated by the autologous segment, accounting for around 60% share of the overall market. Autologous cell therapies involve harvesting the cells from a patient’s own body, making it a preferred technique among patients. Autologous cell therapy manufacturing avoids issues related to rejection by the patient’s immune system, making it the most used technique currently.
The global Cell Therapy Manufacturing Market Size is estimated to be valued at US$ 12.99 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
PEST Analysis
Political: Stringent regulations for cell therapy products are being enforced by regulatory bodies like FDA and EMA to ensure safety and efficacy. This encourages more companies to invest in compliance and manufacturing facilities.
Economic: The cell therapy manufacturing market is growing at a high rate due to rising healthcare spending by governments worldwide to address the increasing Cancer prevalence.
Social: Growing awareness about cell therapies and their benefits is increasing the demand for advanced treatment methods. This acts as a key driver for the manufacturing market.
Technological: rapid developments in cell culturing and differentiation techniques are helping reduce production costs and optimize manufacturing processes. Advanced tools also facilitate large-scale commercial production.
Key Takeaways
The global cell therapy manufacturing market is expected to witness high growth, exhibiting 15% CAGR over the forecast period of 2023 to 2030, due to an increasing prevalence of cancer and chronic diseases. The market size is projected to reach US$ 56.34 Bn by 2030 from US$ 12.99 Mn in 2023.
North America represents the largest and fastest-growing region in the cell therapy manufacturing market owing to the presence of major market players, rising research activities, and increasing funding for cell-based research. The region accounted for around 40% share of the global market in 2023.
Some of the key players operating in the cell therapy manufacturing market include WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HELIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., and Astellas Pharma Inc. These players are focusing on new product launches, expansions, collaborations, and acquisitions to gain a competitive advantage in the market. For instance, in 2022, Thermo Fisher Scientific acquired Brammer Bio to strengthen its position in viral vector manufacturing for cell and gene therapy.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
